Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

SMARCA4-deficient Thoracic Sarcomas: Clinicopathologic Study of 30 Cases With an Emphasis on Their Nosology and Differential Diagnoses.

Perret R, Chalabreysse L, Watson S, Serre I, Garcia S, Forest F, Yvorel V, Pissaloux D, Thomas de Montpreville V, Masliah-Planchon J, Lantuejoul S, Brevet M, Blay JY, Coindre JM, Tirode F, Le Loarer F.

Am J Surg Pathol. 2018 Nov 16. doi: 10.1097/PAS.0000000000001188. [Epub ahead of print]

PMID:
30451731
2.

Clinicopathologic Features of CIC-NUTM1 Sarcomas, a New Molecular Variant of the Family of CIC-fused Sarcomas.

Le Loarer F, Pissaloux D, Watson S, Godfraind C, Galmiche-Rolland L, Silva K, Mayeur L, Italiano A, Michot A, Pierron G, Vasiljevic A, Ranchère-Vince D, Coindre JM, Tirode F.

Am J Surg Pathol. 2018 Nov 6. doi: 10.1097/PAS.0000000000001187. [Epub ahead of print]

PMID:
30407212
3.

Genomic and transcriptomic characterisation of undifferentiated pleomorphic sarcoma of bone.

Ali NM, Niada S, Brini AT, Morris MR, Kurusamy S, Alholle A, Huen D, Antonescu CR, Tirode F, Sumathi V, Latif F.

J Pathol. 2018 Oct 3. doi: 10.1002/path.5176. [Epub ahead of print]

PMID:
30281149
4.

tp53 deficiency causes a wide tumor spectrum and increases embryonal rhabdomyosarcoma metastasis in zebrafish.

Ignatius MS, Hayes MN, Moore FE, Tang Q, Garcia SP, Blackburn PR, Baxi K, Wang L, Jin A, Ramakrishnan A, Reeder S, Chen Y, Nielsen GP, Chen EY, Hasserjian RP, Tirode F, Ekker SC, Langenau DM.

Elife. 2018 Sep 7;7. pii: e37202. doi: 10.7554/eLife.37202.

5.

Genome-wide association study identifies multiple new loci associated with Ewing sarcoma susceptibility.

Machiela MJ, Grünewald TGP, Surdez D, Reynaud S, Mirabeau O, Karlins E, Rubio RA, Zaidi S, Grossetete-Lalami S, Ballet S, Lapouble E, Laurence V, Michon J, Pierron G, Kovar H, Gaspar N, Kontny U, González-Neira A, Picci P, Alonso J, Patino-Garcia A, Corradini N, Bérard PM, Freedman ND, Rothman N, Dagnall CL, Burdett L, Jones K, Manning M, Wyatt K, Zhou W, Yeager M, Cox DG, Hoover RN, Khan J, Armstrong GT, Leisenring WM, Bhatia S, Robison LL, Kulozik AE, Kriebel J, Meitinger T, Metzler M, Hartmann W, Strauch K, Kirchner T, Dirksen U, Morton LM, Mirabello L, Tucker MA, Tirode F, Chanock SJ, Delattre O.

Nat Commun. 2018 Aug 9;9(1):3184. doi: 10.1038/s41467-018-05537-2.

6.

Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.

Pishas KI, Drenberg CD, Taslim C, Theisen ER, Johnson KM, Saund RS, Pop IL, Crompton BD, Lawlor ER, Tirode F, Mora J, Delattre O, Beckerle MC, Callen DF, Sharma S, Lessnick SL.

Mol Cancer Ther. 2018 Sep;17(9):1902-1916. doi: 10.1158/1535-7163.MCT-18-0373. Epub 2018 Jul 11.

PMID:
29997151
7.

Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusions.

Dadone-Montaudié B, Alberti L, Duc A, Delespaul L, Lesluyes T, Pérot G, Lançon A, Paindavoine S, Di Mauro I, Blay JY, de la Fouchardière A, Chibon F, Karanian M, MacGrogan G, Kubiniek V, Keslair F, Cardot-Leccia N, Michot A, Perrin V, Zekri Y, Coindre JM, Tirode F, Pedeutour F, Ranchère-Vince D, Le Loarer F, Pissaloux D.

Mod Pathol. 2018 Nov;31(11):1683-1693. doi: 10.1038/s41379-018-0089-4. Epub 2018 Jun 28.

PMID:
29955147
8.

PAX3-FOXO1 transgenic zebrafish models identify HES3 as a mediator of rhabdomyosarcoma tumorigenesis.

Kendall GC, Watson S, Xu L, LaVigne CA, Murchison W, Rakheja D, Skapek SX, Tirode F, Delattre O, Amatruda JF.

Elife. 2018 Jun 5;7. pii: e33800. doi: 10.7554/eLife.33800.

9.

Complete response to CSF1R inhibitor in a translocation variant of teno-synovial giant cell tumor without genomic alteration of the CSF1 gene.

Brahmi M, Alberti L, Tirode F, Karanian M, Eberst L, Pissaloux D, Cassier P, Blay JY.

Ann Oncol. 2018 Jun 1;29(6):1488-1489. doi: 10.1093/annonc/mdy129. No abstract available.

PMID:
29668829
10.

Genetic analyses of undifferentiated small round cell sarcoma identifies a novel sarcoma subtype with a recurrent CRTC1-SS18 gene fusion.

Alholle A, Karanian M, Brini AT, Morris MR, Kannappan V, Niada S, Niblett A, Ranchère-Vince D, Pissaloux D, Delfour C, Maran-Gonzalez A, Antonescu CR, Sumathi V, Tirode F, Latif F.

J Pathol. 2018 Jun;245(2):186-196. doi: 10.1002/path.5071. Epub 2018 Apr 16.

PMID:
29533464
11.

Transcriptomic definition of molecular subgroups of small round cell sarcomas.

Watson S, Perrin V, Guillemot D, Reynaud S, Coindre JM, Karanian M, Guinebretière JM, Freneaux P, Le Loarer F, Bouvet M, Galmiche-Rolland L, Larousserie F, Longchampt E, Ranchere-Vince D, Pierron G, Delattre O, Tirode F.

J Pathol. 2018 May;245(1):29-40. doi: 10.1002/path.5053. Epub 2018 Mar 30.

PMID:
29431183
12.

BAFfling pathologies: Alterations of BAF complexes in cancer.

Arnaud O, Le Loarer F, Tirode F.

Cancer Lett. 2018 Apr 10;419:266-279. doi: 10.1016/j.canlet.2018.01.046. Epub 2018 Jan 31.

PMID:
29374542
13.

Update on Families of Round Cell Sarcomas Other than Classical Ewing Sarcomas.

Le Loarer F, Pissaloux D, Coindre JM, Tirode F, Vince DR.

Surg Pathol Clin. 2017 Sep;10(3):587-620. doi: 10.1016/j.path.2017.04.002. Epub 2017 Jun 20. Review.

PMID:
28797504
14.

ETV4 is a useful marker for the diagnosis of CIC-rearranged undifferentiated round-cell sarcomas: a study of 127 cases including mimicking lesions.

Le Guellec S, Velasco V, Pérot G, Watson S, Tirode F, Coindre JM.

Mod Pathol. 2016 Dec;29(12):1523-1531. doi: 10.1038/modpathol.2016.155. Epub 2016 Aug 26.

15.

The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report.

Kager L, Whelan J, Dirksen U, Hassan B, Anninga J, Bennister L, Bovée JVMG, Brennan B, Broto JM, Brugières L, Cleton-Jansen AM, Copland C, Dutour A, Fagioli F, Ferrari S, Fiocco M, Fleuren E, Gaspar N, Gelderblom H, Gerrand C, Gerß J, Gonzato O, van der Graaf W, Hecker-Nolting S, Herrero-Martín D, Klco-Brosius S, Kovar H, Ladenstein R, Lancia C, LeDeley MC, McCabe MG, Metzler M, Myklebost O, Nathrath M, Picci P, Potratz J, Redini F, Richter GHS, Reinke D, Rutkowski P, Scotlandi K, Strauss S, Thomas D, Tirado OM, Tirode F, Vassal G, Bielack SS.

Clin Sarcoma Res. 2016 Mar 16;6:3. doi: 10.1186/s13569-016-0043-5. eCollection 2016.

16.

Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model.

Minas TZ, Surdez D, Javaheri T, Tanaka M, Howarth M, Kang HJ, Han J, Han ZY, Sax B, Kream BE, Hong SH, Çelik H, Tirode F, Tuckermann J, Toretsky JA, Kenner L, Kovar H, Lee S, Sweet-Cordero EA, Nakamura T, Moriggl R, Delattre O, Üren A.

Oncotarget. 2017 May 23;8(21):34141-34163. doi: 10.18632/oncotarget.9388.

17.

Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.

Jacques C, Lamoureux F, Baud'huin M, Rodriguez Calleja L, Quillard T, Amiaud J, Tirode F, Rédini F, Bradner JE, Heymann D, Ory B.

Oncotarget. 2016 Apr 26;7(17):24125-40. doi: 10.18632/oncotarget.8214.

18.

Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage.

Alsafadi S, Houy A, Battistella A, Popova T, Wassef M, Henry E, Tirode F, Constantinou A, Piperno-Neumann S, Roman-Roman S, Dutertre M, Stern MH.

Nat Commun. 2016 Feb 4;7:10615. doi: 10.1038/ncomms10615.

19.

The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease.

Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar P, Grünewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, Lawlor E, Lessnick S, Ludwig J, Meltzer P, Metzler M, Mora J, Moriggl R, Nakamura T, Papamarkou T, Radic Sarikas B, Rédini F, Richter GH, Rossig C, Schadler K, Schäfer BW, Scotlandi K, Sheffield NC, Shelat A, Snaar-Jagalska E, Sorensen P, Stegmaier K, Stewart E, Sweet-Cordero A, Szuhai K, Tirado OM, Tirode F, Toretsky J, Tsafou K, Üren A, Zinovyev A, Delattre O.

Oncotarget. 2016 Feb 23;7(8):8613-24. doi: 10.18632/oncotarget.6937. Review.

20.

SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas.

Le Loarer F, Watson S, Pierron G, de Montpreville VT, Ballet S, Firmin N, Auguste A, Pissaloux D, Boyault S, Paindavoine S, Dechelotte PJ, Besse B, Vignaud JM, Brevet M, Fadel E, Richer W, Treilleux I, Masliah-Planchon J, Devouassoux-Shisheboran M, Zalcman G, Allory Y, Bourdeaut F, Thivolet-Bejui F, Ranchere-Vince D, Girard N, Lantuejoul S, Galateau-Sallé F, Coindre JM, Leary A, Delattre O, Blay JY, Tirode F.

Nat Genet. 2015 Oct;47(10):1200-5. doi: 10.1038/ng.3399. Epub 2015 Sep 7.

PMID:
26343384
21.

Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite.

Grünewald TG, Bernard V, Gilardi-Hebenstreit P, Raynal V, Surdez D, Aynaud MM, Mirabeau O, Cidre-Aranaz F, Tirode F, Zaidi S, Perot G, Jonker AH, Lucchesi C, Le Deley MC, Oberlin O, Marec-Bérard P, Véron AS, Reynaud S, Lapouble E, Boeva V, Rio Frio T, Alonso J, Bhatia S, Pierron G, Cancel-Tassin G, Cussenot O, Cox DG, Morton LM, Machiela MJ, Chanock SJ, Charnay P, Delattre O.

Nat Genet. 2015 Sep;47(9):1073-8. doi: 10.1038/ng.3363. Epub 2015 Jul 27.

22.

Development of curative therapies for Ewing sarcomas by interdisciplinary cooperative groups in Europe.

Bölling T, Braun-Munzinger G, Burdach S, Calaminus G, Craft A, Delattre O, Deley MC, Dirksen U, Dockhorn-Dworniczak B, Dunst J, Engel S, Faldum A, Fröhlich B, Gadner H, Göbel U, Gosheger G, Hardes J, Hawkins DS, Hjorth L, Hoffmann C, Kovar H, Kruseova J, Ladenstein R, Leuschner I, Lewis IJ, Oberlin O, Paulussen M, Potratz J, Ranft A, Rössig C, Rübe C, Sauer R, Schober O, Schuck A, Timmermann B, Tirode F, van den Berg H, van Valen F, Vieth V, Willich N, Winkelmann W, Whelan J, Womer RB.

Klin Padiatr. 2015 May;227(3):108-15. doi: 10.1055/s-0035-1545263. Epub 2015 May 18.

PMID:
25985445
23.

Translational Activation of HIF1α by YB-1 Promotes Sarcoma Metastasis.

El-Naggar AM, Veinotte CJ, Cheng H, Grunewald TG, Negri GL, Somasekharan SP, Corkery DP, Tirode F, Mathers J, Khan D, Kyle AH, Baker JH, LePard NE, McKinney S, Hajee S, Bosiljcic M, Leprivier G, Tognon CE, Minchinton AI, Bennewith KL, Delattre O, Wang Y, Dellaire G, Berman JN, Sorensen PH.

Cancer Cell. 2015 May 11;27(5):682-97. doi: 10.1016/j.ccell.2015.04.003.

24.

Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.

Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, Zhang Z, Lapouble E, Grossetête-Lalami S, Rusch M, Reynaud S, Rio-Frio T, Hedlund E, Wu G, Chen X, Pierron G, Oberlin O, Zaidi S, Lemmon G, Gupta P, Vadodaria B, Easton J, Gut M, Ding L, Mardis ER, Wilson RK, Shurtleff S, Laurence V, Michon J, Marec-Bérard P, Gut I, Downing J, Dyer M, Zhang J, Delattre O; St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project and the International Cancer Genome Consortium.

Cancer Discov. 2014 Nov;4(11):1342-53. doi: 10.1158/2159-8290.CD-14-0622. Epub 2014 Sep 15.

25.

Osteoprotegerin inhibits bone resorption and prevents tumor development in a xenogenic model of Ewing's sarcoma by inhibiting RANKL.

Picarda G, Matous E, Amiaud J, Charrier C, Lamoureux F, Heymann MF, Tirode F, Pitard B, Trichet V, Heymann D, Redini F.

J Bone Oncol. 2013 May 20;2(3):95-104. doi: 10.1016/j.jbo.2013.04.004. eCollection 2013 Sep.

26.

Systems biology of Ewing sarcoma: a network model of EWS-FLI1 effect on proliferation and apoptosis.

Stoll G, Surdez D, Tirode F, Laud K, Barillot E, Zinovyev A, Delattre O.

Nucleic Acids Res. 2013 Oct;41(19):8853-71. doi: 10.1093/nar/gkt678. Epub 2013 Aug 8.

27.

Loss of connexin43 expression in Ewing's sarcoma cells favors the development of the primary tumor and the associated bone osteolysis.

Talbot J, Brion R, Picarda G, Amiaud J, Chesneau J, Bougras G, Stresing V, Tirode F, Heymann D, Redini F, Verrecchia F.

Biochim Biophys Acta. 2013 Apr;1832(4):553-64. doi: 10.1016/j.bbadis.2013.01.001. Epub 2013 Jan 9.

28.

Bone sarcomas: from biology to targeted therapies.

Gaspar N, Di Giannatale A, Geoerger B, Redini F, Corradini N, Enz-Werle N, Tirode F, Marec-Berard P, Gentet JC, Laurence V, Piperno-Neumann S, Oberlin O, Brugieres L.

Sarcoma. 2012;2012:301975. doi: 10.1155/2012/301975. Epub 2012 Nov 27.

29.

Oncostatin M is a growth factor for Ewing sarcoma.

David E, Tirode F, Baud'huin M, Guihard P, Laud K, Delattre O, Heymann MF, Heymann D, Redini F, Blanchard F.

Am J Pathol. 2012 Nov;181(5):1782-95. doi: 10.1016/j.ajpath.2012.07.023. Epub 2012 Sep 13.

PMID:
22982441
30.

Targeting the EWSR1-FLI1 oncogene-induced protein kinase PKC-β abolishes ewing sarcoma growth.

Surdez D, Benetkiewicz M, Perrin V, Han ZY, Pierron G, Ballet S, Lamoureux F, Rédini F, Decouvelaere AV, Daudigeos-Dubus E, Geoerger B, de Pinieux G, Delattre O, Tirode F.

Cancer Res. 2012 Sep 1;72(17):4494-503. Epub 2012 Aug 28.

31.

Antagonism pattern detection between microRNA and target expression in Ewing's sarcoma.

Martignetti L, Laud-Duval K, Tirode F, Pierron G, Reynaud S, Barillot E, Delattre O, Zinovyev A.

PLoS One. 2012;7(7):e41770. doi: 10.1371/journal.pone.0041770. Epub 2012 Jul 25.

32.

The first European interdisciplinary ewing sarcoma research summit.

Kovar H, Alonso J, Aman P, Aryee DN, Ban J, Burchill SA, Burdach S, De Alava E, Delattre O, Dirksen U, Fourtouna A, Fulda S, Helman LJ, Herrero-Martin D, Hogendoorn PC, Kontny U, Lawlor ER, Lessnick SL, Llombart-Bosch A, Metzler M, Moriggl R, Niedan S, Potratz J, Redini F, Richter GH, Riedmann LT, Rossig C, Schäfer BW, Schwentner R, Scotlandi K, Sorensen PH, Staege MS, Tirode F, Toretsky J, Ventura S, Eggert A, Ladenstein R.

Front Oncol. 2012 May 29;2:54. doi: 10.3389/fonc.2012.00054. eCollection 2012.

33.

A new subtype of bone sarcoma defined by BCOR-CCNB3 gene fusion.

Pierron G, Tirode F, Lucchesi C, Reynaud S, Ballet S, Cohen-Gogo S, Perrin V, Coindre JM, Delattre O.

Nat Genet. 2012 Mar 4;44(4):461-6. doi: 10.1038/ng.1107.

PMID:
22387997
34.

Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma.

Postel-Vinay S, Véron AS, Tirode F, Pierron G, Reynaud S, Kovar H, Oberlin O, Lapouble E, Ballet S, Lucchesi C, Kontny U, González-Neira A, Picci P, Alonso J, Patino-Garcia A, de Paillerets BB, Laud K, Dina C, Froguel P, Clavel-Chapelon F, Doz F, Michon J, Chanock SJ, Thomas G, Cox DG, Delattre O.

Nat Genet. 2012 Feb 12;44(3):323-7. doi: 10.1038/ng.1085.

PMID:
22327514
35.

A functional, new short isoform of death receptor 4 in Ewing's sarcoma cell lines may be involved in TRAIL sensitivity/resistance mechanisms.

Picarda G, Surget S, Guiho R, Téletchéa S, Berreur M, Tirode F, Pellat-Deceunynck C, Heymann D, Trichet V, Rédini F.

Mol Cancer Res. 2012 Mar;10(3):336-46. doi: 10.1158/1541-7786.MCR-11-0390. Epub 2012 Jan 18.

36.

Zoledronic acid as a new adjuvant therapeutic strategy for Ewing's sarcoma patients.

Odri GA, Dumoucel S, Picarda G, Battaglia S, Lamoureux F, Corradini N, Rousseau J, Tirode F, Laud K, Delattre O, Gouin F, Heymann D, Redini F.

Cancer Res. 2010 Oct 1;70(19):7610-9. doi: 10.1158/0008-5472.CAN-09-4272. Epub 2010 Sep 14.

37.

EWS-FLI1 inhibits TNFalpha-induced NFkappaB-dependent transcription in Ewing sarcoma cells.

Lagirand-Cantaloube J, Laud K, Lilienbaum A, Tirode F, Delattre O, Auclair C, Kryszke MH.

Biochem Biophys Res Commun. 2010 Sep 3;399(4):705-10. doi: 10.1016/j.bbrc.2010.08.004. Epub 2010 Aug 5.

PMID:
20691659
38.

Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity.

Chibon F, Lagarde P, Salas S, Pérot G, Brouste V, Tirode F, Lucchesi C, de Reynies A, Kauffmann A, Bui B, Terrier P, Bonvalot S, Le Cesne A, Vince-Ranchère D, Blay JY, Collin F, Guillou L, Leroux A, Coindre JM, Aurias A.

Nat Med. 2010 Jul;16(7):781-7. doi: 10.1038/nm.2174. Epub 2010 Jun 27.

PMID:
20581836
39.

De novo motif identification improves the accuracy of predicting transcription factor binding sites in ChIP-Seq data analysis.

Boeva V, Surdez D, Guillon N, Tirode F, Fejes AP, Delattre O, Barillot E.

Nucleic Acids Res. 2010 Jun;38(11):e126. doi: 10.1093/nar/gkq217. Epub 2010 Apr 7.

40.

Preclinical evidence that use of TRAIL in Ewing's sarcoma and osteosarcoma therapy inhibits tumor growth, prevents osteolysis, and increases animal survival.

Picarda G, Lamoureux F, Geffroy L, Delepine P, Montier T, Laud K, Tirode F, Delattre O, Heymann D, Rédini F.

Clin Cancer Res. 2010 Apr 15;16(8):2363-74. doi: 10.1158/1078-0432.CCR-09-1779. Epub 2010 Apr 6.

41.

The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function.

Guillon N, Tirode F, Boeva V, Zynovyev A, Barillot E, Delattre O.

PLoS One. 2009;4(3):e4932. doi: 10.1371/journal.pone.0004932. Epub 2009 Mar 23.

42.

Strong smooth muscle differentiation is dependent on myocardin gene amplification in most human retroperitoneal leiomyosarcomas.

Pérot G, Derré J, Coindre JM, Tirode F, Lucchesi C, Mariani O, Gibault L, Guillou L, Terrier P, Aurias A.

Cancer Res. 2009 Mar 15;69(6):2269-78. doi: 10.1158/0008-5472.CAN-08-1443. Epub 2009 Mar 10.

43.

[Stem cells and connective-tissue tumors: Ewing's sarcoma].

Tirode F, Delattre O.

Ann Pathol. 2008 Nov;28 Spec No 1(1):S33-4. doi: 10.1016/j.annpat.2008.09.006. Epub 2008 Oct 11. French. No abstract available.

PMID:
18984293
44.

[Cellular origin of Ewing's tumor. A corner of the veil is lifted].

Tirode F, Laud-Duval K, Delattre O.

Med Sci (Paris). 2008 Mar;24(3):248-50. doi: 10.1051/medsci/2008243248. French. No abstract available.

45.

Mesenchymal stem cell features of Ewing tumors.

Tirode F, Laud-Duval K, Prieur A, Delorme B, Charbord P, Delattre O.

Cancer Cell. 2007 May;11(5):421-9.

46.

The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors.

Mendiola M, Carrillo J, García E, Lalli E, Hernández T, de Alava E, Tirode F, Delattre O, García-Miguel P, López-Barea F, Pestaña A, Alonso J.

Int J Cancer. 2006 Mar 15;118(6):1381-9.

48.

Three-hybrid screens. Inducible third-party systems.

Sandrock B, Tirode F, Egly JM.

Methods Mol Biol. 2001;177:271-89. No abstract available.

PMID:
11530612
49.

Nucleotide excision repair of DNA with recombinant human proteins: definition of the minimal set of factors, active forms of TFIIH, and modulation by CAK.

Araújo SJ, Tirode F, Coin F, Pospiech H, Syväoja JE, Stucki M, Hübscher U, Egly JM, Wood RD.

Genes Dev. 2000 Feb 1;14(3):349-59.

50.

Bisphosphonate effects in rat unloaded hindlimb bone loss model: three-dimensional microcomputed tomographic, histomorphometric, and densitometric analyses.

Barou O, Lafage-Proust MH, Martel C, Thomas T, Tirode F, Laroche N, Barbier A, Alexandre C, Vico L.

J Pharmacol Exp Ther. 1999 Oct;291(1):321-8.

Supplemental Content

Loading ...
Support Center